CN1616090A - Medicine for treating radioactive membrana mucosa damage, repeative aphtha and paradentitis - Google Patents
Medicine for treating radioactive membrana mucosa damage, repeative aphtha and paradentitis Download PDFInfo
- Publication number
- CN1616090A CN1616090A CNA2004100438949A CN200410043894A CN1616090A CN 1616090 A CN1616090 A CN 1616090A CN A2004100438949 A CNA2004100438949 A CN A2004100438949A CN 200410043894 A CN200410043894 A CN 200410043894A CN 1616090 A CN1616090 A CN 1616090A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- medicine
- gram
- superoxide dismutase
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to medicine, and is medicine for treating radioactive mucous membrane damage, recurrent aphtha and paradentitis. The medicine contains SOD, vitamin B12 and vitamin B2, and may be aerosol or oral lozenge. The aerosol product has the components of SOD 20000-100000 IU, vitamin B12 0.001-0.005 g and vitamin B2 0.005-0.015 g. The oral lozenge product has the components of SOD 1000-4000 IU, vitamin B12 0.000009-0.00009 g and vitamin B2 0.0002-0.0008 g. The medicine has wide material source, low cost, and other advantages.
Description
Technical field:
The present invention relates to a kind of medicine.
Background technology:
Cancer patient is in radiation therapy process, because the effect of active oxygen can make normal structure damage simultaneously, causes general reaction, causes composition decline in the blood as bone marrow depression, and leukocyte, erythrocyte, platelet counts reduce, nauseating, vomiting, and physical ability descends.The local normal structure of irradiated site can be damaged, and can cause the oropharynx mucosa that rotten to the corn, ulcer take place as incidence radiotherapy, even downright bad.Patient's pain is unusual, and can be heavier because of damage, must interrupt radiotherapy, and this makes cancerous cell that breathing spell be arranged, and propagation again takes place to quicken, and this is unfavorable to cancer control.When breast tumor radiotherapy, the order of severity of patient's radioactivity esophagus increases to some extent, and severe patient is taken food because of the pain influence, even needs to interrupt radiotherapy, affects the treatment, and does not still have effective solution at present.Previously the radiotherapy mucosa injury has systemic administration and local application, and systemic administration adopts antibiotics to add the intravenous drip of cortex hormone more.Radiation injury is the aseptic inflammatory reaction, and under no concurrent infection situation, antibiotics does not have direct therapeutical effect.The 17-hydroxy-11-dehydrocorticosterone antiinflammatory action is nonspecific, too much uses regular meeting and brings many untoward reaction to human body, is not better than local application according to our observing effect.Oropharynx mucosa radiation injury local application is often adopted following method: many shellfishes liquid rinsing the mouth, it does not have direct therapeutical effect; Vitamin B
12It has inconvenience local application, and the shortcoming that dose is inaccurate is used VB in the past
12Or Wisk local application, lot of V B
12Enter in the body considerably beyond VB clinically
12Common dose; Product Wisk, i.e. compound vitamin B appearred in 1998
12Solution now passes through new gram with trade name, and it consists of 25ml solution and includes VB
1212500 μ g, gentamycin 20000 units.Its initial description can be done spray delivery, VB when treatment oropharynx mucosa radiation injury
12Enter that amount reached for 2500 microgram/days in the body, although this medicine is nontoxic, dosage is VB at ordinary times
12Five times of treatment indication disease.We think irrational and be used for aseptic inflammation for the local application, particularly routine of gentamycin.Now this medicine is classified as medicine for external use by country, and indication only is used for the radioactive skin II～III degree of burning, and merges traumatic infection.Recurrent aphtha is to occur isolated circle repeatedly or oval shallow-layer aphtha is a feature with oral mucosa, and outbreak influences feed often and sleeps because of having an intense pain, and the cause of disease is still indeterminate, may be all multifactor relevant with immunity etc.Previously treatment vitamins commonly used is oral, and local XILEI SAN, BINGPENG SAN, watermelon crystal, cydiodine, the cetacort pad pasting etc. used are observed said medicine analgesic effect and not obvious according to us, and it is little to shorten the stadium scope.The medicine of oral local administration treatment periodontitis is not seldom more seen the medicine that promotion postoperation of oral cavity wound healing is arranged.Therefore, the medicine that lacks effective local application treatment mouth, pharynx, esophagus mucosa radiation injury at present.
Summary of the invention:
The object of the present invention is to provide the medicine of a kind of curative effect obvious treatment radioactivity mucosa injury, recurrent aphtha, periodontitis, comprise superoxide dismutase, vitamin B in its composition simultaneously
12And vitamin B
2, when products made thereby was aerosol, the consumption of each composition was: the superoxide dismutase of per 20000～100000 units, used vitamin B
120.001～0.005 gram, used vitamin B
20.005～0.015 gram; When products made thereby was buccal tablet, the consumption of each composition was: the superoxide dismutase of per 1000～4000 units, used vitamin B
120.000009～0.00009 gram, used vitamin B
20.0002～0.0008 gram.VB among the present invention
12The most normal 50～150 microgram/days of range of application of every day, for clinical common dose 1/3～1/10, to recurrent aphtha, illness such as periodontitis, dosage can be lower, so not only makes human body safer, saved cost, and can obtain obvious therapeutic effect; The experiment of superoxide dismutase (SOD) product is proof also, nontoxic by the real genus of six grades of point-scores of China's food toxicology, the dosage that we use SOD intake in present many health product, therefore, all prove theoretically or in the practice, our preparation is without any side effects, and a small amount of application can play health-care effect.Buccal tablet of the present invention is easy to use, and therapeutic effect such as obvious alleviating pain are arranged.Medicine of the present invention all is better than existing any other method of being taked clinically at aspects such as promoting wound healing, pain relieving, relief of symptoms.And patient economy burden is little, and the pain that radiation mucositis or recurrent aphtha are caused promptly produced analgesic effect in 5～10 minutes after the medication.But this preparation does not certainly have narcotic analgesic medicine composition, after the medication in the patient oral cavity rheuminess thing obviously reduce.Medicine medicine of the present invention source is abundant, cheap, easy to make, is convenient to store, transport.The patient carries with easy to use.Owing to be drying agent, guaranteed the effect duration of SOD, the buccal tablet mouthfeel is good, free from extraneous odour, a small amount of application may be done oral cavity and whole body health-care effect, and is therefore practical.Medicine of the present invention is to recurrent aphtha, and oral diseases such as periodontitis have instant effect, and analgesic effect is obvious, promotes wound healing, and the operation on oral cavity otch is had the healing of promotion effect.
The specific embodiment:
The specific embodiment one: comprise superoxide dismutase, vitamin B in the composition of present embodiment simultaneously
12And vitamin B
2, when products made thereby was aerosol, the consumption of each composition was: the superoxide dismutase of per 20000～100000 units, used vitamin B
120.001～0.005 gram, used vitamin B
20.005～0.015 gram.
The specific embodiment two: contain following composition in the present embodiment: distilled water 75ml, glycerol 15ml, dehydrated alcohol 10ml are total to 100ml as adjuvant, i.e. solvent; Superoxide dismutase (SOD) 20000～100000 units, vitamin B
120.001～0.005 gram, vitamin B
20.005～0.015 gram, as major ingredient, i.e. solute.In the said components, adjuvant is not simple water preparation, and ethanol plays the antiseptic and inhibiting bacteria function effect in the component, and topical application promotes blood circulation, helps drug osmotic, the performance drug effect; The glycerol composition helps medicine and is adsorbed in the pathological changes surface, and solution is little sweet, free from extraneous odour, and mouthfeel is good.
The specific embodiment three: the composition in the present embodiment is as follows: superoxide dismutase 40000 units, vitamin B
120.002 gram, vitamin B
20.012 gram, distilled water 75ml, glycerol 15ml, dehydrated alcohol 10ml.
Its production method is only all the components to be mixed in proportion getting final product.Can put into laryngeal spray during use, concrete using method is identical with following embodiment four.
The specific embodiment four: present embodiment is the preparation process of aerosol: it is in the dark brown peace bottle of 30ml that the sterile filling major ingredient is gone into capacity, puts corresponding aerosol and sprays first, and concrete dosage is: superoxide dismutase (SOD): 10000 units, vitamin B
120.0005 gram, vitamin B
20.003 gram; 25ml adjuvant sterile filling is gone into capacity in the 30ml ordinary white peace bottle, and two bottles are listed as a packing.Aforementioned packing adopts major-minor packing, and major ingredient is loaded in the shading bottle, has guaranteed pharmaceutically active, has solved the enzyme preparation problem that effect duration lacks in water preparation.Use is opened two bottles before, adjuvant is poured in the major ingredient bottle shake up, and puts the aerosol shower nozzle on bottle, and the spraying of boil on the nape opposite the mouth intracavity affected part is used, and 5～15 times/day, each 3～5 times.According to state of an illness difference, every bottle can use up on the 3rd～7, as the medicine residue of recovering, and can preserve in refrigerator cold-storage or dark cold place.
The specific embodiment five: the concrete consumption of each composition when the present embodiment products made thereby is buccal tablet: adjuvant is sucrose and lactose, both part by weight 2: 1; Add following major ingredient in every gram adjuvant: the superoxide dismutase of 1000～4000 units, vitamin B
120.000009～0.00009 gram, vitamin B
20.0002～0.0008 gram.
The specific embodiment six: the concrete consumption of present embodiment composition is: adjuvant is sucrose and lactose, both part by weight 2: 1; Add following major ingredient in every gram adjuvant: superoxide dismutase 1000～4000 units, vitamin B
120.000009～0.00009 gram, vitamin B
20.0002～0.0008 gram, vitamin B
60.0015～0.015 gram, vitamin B
10.0015～0.015 gram.
The specific embodiment seven: in the present embodiment, adjuvant is sucrose and lactose, both part by weight 2: 1; Add following major ingredient in every gram adjuvant: superoxide dismutase 2000 units, vitamin B
120.000018 gram, vitamin B
20.0004 gram.
The specific embodiment eight: in the present embodiment, adjuvant is sucrose and lactose, both part by weight 2: 1; Add following major ingredient in every gram adjuvant: superoxide dismutase 2000 units, vitamin B
120.000018 gram, vitamin B
20.0004 gram, vitamin B
60.003 gram, vitamin B
10.003 gram.
The processing method of buccal tablet of the present invention is known: lactose and sucrose pulverizing were taken out 120 mesh sieve powder, and both are mixed in proportion.Requirement according to dosage, major ingredient and adjuvant are doubly measured dilution and are finished, and 120 mesh sieve secondary mixing are even, and an amount of sucrose solution that adds mass concentration 10% is granulated, and granulate is beaten sheet with special-shaped tablet machine after the drying at room temperature, and every weight is 0.5 gram.Tablet of the present invention more is applicable to the patient of recurrent aphtha, periodontitis, can make medicine directly press close to diseased region and give full play to drug effect.
Using method is: at interval contain with 3～15 slice according to the state of an illness needs every day, must make medicine or solution touch the affected part, and mouthful endocrine or impurity are too much, should gargle earlier.
Principle of the present invention is: (1) ultra-oxygen anion free radical (O
2 -) be that a kind of life-span is long, active extremely strong active oxygen, the O that produces in the radiotherapy
2 -Very big to body injury.Superoxide dismutase (SOD) is the unique enzyme that can eliminate free radical.SOD is at defying age; the treatment cardiovascular diseases, directive effects such as diabetes are in research, and these diseases also exist the reduction of SOD level relevant with activity in vivo oxygen; studies have shown that SOD to radioactive biomembrane damage, bone marrow injury all has protective effect, can reduce the raying mouse death rate.External source gives SOD and can prevent and improve radiation and cause inflammatory reaction.The existing report of oral diseases such as SOD single therapy recurrent aphtha, so we adopt compound recipe SOD preparation to prevent and the radiotherapy mucosa injury has sufficient theoretical foundation, and in clinical research, obtain clear and definite effect.
(2) vitamin B in the component
12(VB
12) participate in body fat and proteinic metabolism, be the important coenzyme of synthetic methionine, help DNA synthetic, promote to repair.Participate in lipid metabolism, synthetic to lipid in the neural myelin, maintenance maincenter and myelin nerve fiber functional completeness is extremely important on every side, this is VB
12The mechanism of analgesic effect.VB
12Can make the sulfydryl enzyme keep activated state, and mostly existing radiation protective is compounds containing thiol groups, by passing the hydrogen effect, metabolism free radical and peroxide.
(3) VB
2Be the prothetic group of yellow enzymes in sugar in the body, fat, the protein metabolism, work the hydrogen effect of passing.Be usually used in skin mucosa illness such as angular cheilitis, conjunctivitis, scrotitis clinically.Clinically, the doctor sometimes the mixing batter shape be used for mucosa ulcer.
By top argumentation and our cognition SOD, VB in practice
12, VB
2Being the splendid combination of treatment and the radiation damage of prevention mucosa, and can removing interior free yl and oxidation product by body is interior to Absorptions such as SOD, play the effect that alleviates the total body radiation reaction, is the two birds of a stone.Because this preparation has anti-inflammatory analgesic, promote repair, be used for recurrent aphtha, periodontitis, promotion postoperation of oral cavity wound healing, positive effect is also arranged.We also prove by practical observation that it is a kind of synergism that three medicines share, and use any separately or two kinds of its therapeutic effect of composition obviously reduce.
The present invention has the wound healing of promotion effect, can be used for promoting wound healing behind the operation on oral cavity therefore that this medicine also has defying age, radiation resistance, and an amount of the use has health-care effect.
The pharmacodynamic experiment summary:
One. tumor of head and neck 130 examples (nasopharyngeal carcinoma 92 examples, other 38 examples) are controlled in radiation, are divided into matched group at random, and (ingredient is SOD+VB to treat 1 group
12), (ingredient is SOD+VB to treat 2 groups
12+ VB
2).The treatment group begins medication when all the radiation reaction of I level appearred in oral mucosa in 5～10 days after patient's radiotherapy, and medicine is sprayed 5～15 times with laryngeal spray every day in the affected part, oral cavity, and every day, consumption did not wait at 5～15ml; Matched group adopts watermelon crystal, many shellfishes liquid rinsing the mouth, or antibiotics adds cortex hormone dead point, and the mucosa reaction is as follows by level Four evaluation situation after the medication:
| Group | The I level | The II level | The III level | The IV level |
| Matched group | ????0 | ????30 | ????14 | ????0 |
| Treat 1 group | ????3 | ????35 | ????6 | ????0 |
| Treat 2 groups | ????9 | ????32 | ????1 | ????0 |
Statistical procedures, in twos between contrast marked difference (P＜0.05) all arranged.
Aforementioned contrast experiment as can be seen, the effect for the treatment of 2 groups obviously is better than two groups of fronts.
Two .SOD buccal tablet radiotherapy oral mucosa damage 16 examples, contain 4～10 every day and do not wait, and the result is as follows:
| Group | The I level | The II level | The III level | The IV level |
| Before the treatment | ????0 | ????12 | ????4 | ????0 |
| After the treatment | ????8 | ????7 | ????1 | ????0 |
Among the 4 routine III level mucositis patients, weigh the preceding hard palate portion of example treatment mucosa sheet most and come off, and hemorrhage on a small quantity, and pain is serious.The atomizing of dead point antimicrobial drug and oropharynx sucks not have in 20 days and takes a turn for the better, oral buccal tablet of the present invention, the same day pain relief, second day, can advance one in bread, and not need use blister, medication patient's mucosa on the 10th reacts and transfers the II level to.Two routine III order reaction patients transfer I and II level respectively in addition.An invalid example is a gums cancer postoperative local nerve paralysis, and medication 3 days identifies oneself the bad and drug withdrawal of effect.We know from experience, and early stage, lasting, an amount of medication is effective.Mucosa injury is heavy, wound surface big, dark, repair inevitable slow.
Three. with radioactivity esophagitis 10 examples that buccal tablet of the present invention treatment causes because of pulmonary carcinoma radiotherapy, do not wait 5～12 of every days, containing the back promptly had 3 routine pharyngeal pain reliefs the same day, and conscious feed is smooth and easy; 5 examples are swallowed pain in three days and are obviously alleviated, but there is the pain in 2 routine patient's esophagus stage casings more obvious always, traces it to its cause, due to the long composite factor of possible esophagus range of exposures, I also see that an esophagus radiotherapy patient puts back esophagus long period pain, but barium does not see that thoroughly esophagus has obvious pathological changes.
Four. with buccal tablet treatment recurrent aphtha 8 examples of the present invention, contain 3～8 every day and get final product, medicine is close to the affected part when containing, general sustainable 4 hours of analgesic effect, pain relieving fully in 2～3 days after the medication.Can shift to an earlier date about 5 days recovery time with the own control ulcer surface.It is medication just that one routine patient's stomatalgia is arranged, and ulcer does not form, and we know from experience is that the medication effect is obvious in early days for all patient's pathological changes.
Five. with buccal tablet treatment patients with periodontitis two examples of the present invention, an example is the water preparation spraying, medication during morbidity, the reducing swelling and alleviating pain effect is obvious; Another example contains back detumescence on the same day for diabetics, and pain stops fully, only uses 2～3 every day, and the readme effect is not second to the periodontal health.
Six. with aerosol operation on oral cavity wound healing patient four examples of the present invention, all adopt water preparation, spray medicine every day 5～10 times.One example is a lip mucosa sialocele, excision back 42 hours, and suture is bitten off when having a meal, and the discovery otch heals fully; 3 examples are hard palate portion tumor in addition, and two examples are mixed tumor, and an example is malignant melanoma (disliking black).Hard palate portion operative incision is big, and postoperative needs the gauze filling, the growth of inwardly creeping of incision periphery portion mucosa, and the general minimum of wound healing needs more than the first quarter moon; The healing in ten days of two routine mixed tumor patient's postoperatives.Another is disliked black corrective surgery hard palate is excised fully, and wound surface is big, presses experience in the past, and gauze is clogged needs first quarter moon to take out, the minimum need of wound healing one month, and also disunion forever, but promptly healed fully in 20 days with aerosol of the present invention.
Claims (6)
1, the medicine of a kind of radiotherapy mucosa injury, recurrent aphtha, periodontitis is characterized in that comprising superoxide dismutase, vitamin B simultaneously in its composition
12And vitamin B
2, when products made thereby was aerosol, the consumption of each composition was: the superoxide dismutase of per 20000～100000 units, used vitamin B
120.001～0.005 gram, used vitamin B
20.005～0.015 gram.
2, the medicine of radiotherapy mucosa injury according to claim 1, recurrent aphtha, periodontitis is characterized in that the consumption of each composition is: the superoxide dismutase of per 40000 units, used vitamin B
120.002 gram, used vitamin B
20.012 gram.
3, the medicine of radiotherapy mucosa injury according to claim 1 and 2, recurrent aphtha, periodontitis, it is characterized in that also comprising distilled water, glycerol and dehydrated alcohol in its composition, the superoxide dismutase of per 20000～100000 units is used distilled water 75ml, glycerol 15ml, dehydrated alcohol 10ml.
4, the medicine of a kind of radiotherapy mucosa injury, recurrent aphtha, periodontitis is characterized in that comprising superoxide dismutase, vitamin B simultaneously in its composition
12And vitamin B
2, when products made thereby was buccal tablet, the consumption of each composition was: the superoxide dismutase of per 1000～4000 units, used vitamin B
120.000009～0.00009 gram, used vitamin B
20.0002～0.0008 gram.
5, the medicine of radiotherapy mucosa injury according to claim 4, recurrent aphtha, periodontitis is characterized in that the consumption of each composition is: the superoxide dismutase of per 2000 units, used vitamin B
120.000018 gram, used vitamin B
20.0004 gram.
6,, it is characterized in that also comprising vitamin B in its composition according to the medicine of claim 4 or 5 described radiotherapy mucosa injurys, recurrent aphtha, periodontitis
6And vitamin B
1, the superoxide dismutase of per 1000～4000 units is used vitamin B
60.0015～0.015 gram, vitamin B
10.0015～0.015 gram.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410043894 CN1289144C (en) | 2004-09-24 | 2004-09-24 | Medicine for treating radioactive membrana mucosa damage, repeative aphtha and paradentitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410043894 CN1289144C (en) | 2004-09-24 | 2004-09-24 | Medicine for treating radioactive membrana mucosa damage, repeative aphtha and paradentitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1616090A true CN1616090A (en) | 2005-05-18 |
| CN1289144C CN1289144C (en) | 2006-12-13 |
Family
ID=34763780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410043894 Expired - Fee Related CN1289144C (en) | 2004-09-24 | 2004-09-24 | Medicine for treating radioactive membrana mucosa damage, repeative aphtha and paradentitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1289144C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100428955C (en) * | 2005-10-31 | 2008-10-29 | 张力元 | Composition of protective agent for radiation damage |
| CN100448484C (en) * | 2005-10-31 | 2009-01-07 | 张力元 | Spray agent for shielding ray in medical use |
-
2004
- 2004-09-24 CN CN 200410043894 patent/CN1289144C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100428955C (en) * | 2005-10-31 | 2008-10-29 | 张力元 | Composition of protective agent for radiation damage |
| CN100448484C (en) * | 2005-10-31 | 2009-01-07 | 张力元 | Spray agent for shielding ray in medical use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1289144C (en) | 2006-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107049993A (en) | A kind of scorching film of the anti-oral ulcer containing alkannin and preparation and application | |
| CN110384725B (en) | A Chinese medicinal composition for regulating oral flora and preparation method of active extract thereof | |
| CN1279582A (en) | Serotonin containing formulation or oral administration and method of use | |
| CN109453169B (en) | Application of bulleyaconitine A | |
| CN1289144C (en) | Medicine for treating radioactive membrana mucosa damage, repeative aphtha and paradentitis | |
| CN1284585C (en) | Medicine for treating acute and chronic pharyogolaryngitis, recurring oral cavity sore and its preparation method | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN1907374A (en) | Chinese medicinal composition for treating oral disease | |
| CN100355432C (en) | Chinese and western compounded drug for treating alveolysis and its preparing method | |
| CN101199492A (en) | Application of oligomerization xylose and xylito in coating slice coating | |
| CN1171594C (en) | Composition containing pearl powder and ascorbic acid | |
| CN115919918B (en) | Application of luffa alcohol precipitation extract | |
| CN108299372A (en) | It is a kind of to be used to prevent drug of gingivitis and preparation method thereof | |
| CN109432082B (en) | Pharmaceutical composition for preventing and treating chemical liver injury | |
| CN102225082A (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof | |
| CN1108160C (en) | Medicine for curing stomatocace and its preparation method | |
| CN101919799B (en) | Novel sustained-release transdermal medicament delivery system | |
| TWI815349B (en) | Use of mangosteen fruit shell extract in the preparation of a medicament for promoting wound healing in diabetes | |
| CN1101276A (en) | External-use medicine composition for vaginitis | |
| CN1954841A (en) | Medicine for treating chronic pharyngitis | |
| CN1172702C (en) | Sugar-free erigeron breviscapus granule and its prepn and application | |
| CN1861072A (en) | Use of malic polyphenols for preparing medicines to treat bronchitis or asthma | |
| CN1437935A (en) | Method for preparing medicine for relieving cough and reducing sputum | |
| CN1045534C (en) | Compound medicine for treating wart | |
| KR0132535B1 (en) | Process for preparing soft tablet consisting of outer shell and inner core |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061213 |